Blosozumab

From Wikipedia, the free encyclopedia
Blosozumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target SOST
Clinical data
Legal status ?
Identifiers
CAS number 1132758-87-2 N
ATC code None
KEGG D10094 N
Chemical data
Formula C6462H9852N1684O2030S46 
Mol. mass 144.63 kDa
 N (what is this?)  (verify)

Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.[1]

Blosozumab was developed by Eli Lilly and Company.

References

  1. ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information 25 (2). 
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
Bone ("-os-", "-s(o)-")
Human ("-osu-")
Humanized ("-sozu-")
Musculoskeletal ("-mul-")
Human ("-mulu-")
Circulatory ("-c(i[r])-")
Human ("-ciru-")
Mouse ("-ciro-")
Chimeric ("-cixi-")
Humanized ("-cizu-")
Neurologic ("-ne(u)(r)-")
Human ("-neru-")
Humanized ("-nezu-"/"-neuzu-")
Angiogenesis inhibitor ("-anibi-")
Humanized ("-anibizu-")


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.